CHAPTER 1: The challenges of pricing innovative drugs

Abstract

Ight of the debates on the new products for the treatment of hepatitis C and cancer, thiswave of innovation raises questions about the ability of our health insurance systems tobear the expense and pay the price claimed by the laboratories. This situation has led toa reflection on the criteria for setting the price of drugs. Public authorities have developednew regulatory mechanisms and have opened a debate to explore new rules that wouldtake into account – in the construction of contracts and prices – real world evidence.Keywords:Drugs, progress, health care costs, health economics, quality adjuste